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Isolation and Characterization of Gentamycin C1 
Sarah Elizabeth Trotman 
Mentor: Dr. Engin H. Serpersu 
Abstract 
Aminoglycoside antibiotics have been used as an effective means of treating 
bacterial infections for many years. However, these drugs have been over prescribed, 
which led to the development of resistance in pathogenic bacteria. The resistance has 
been conferred to the bacteria primarily through R plasmids, and the organisms can now 
produce proteins that effectively disarm an aminoglycoside. 
The focus of this project has been to characterize one component of the 
gentamycin complex, gentamycin C1• After its isolation from the complex, the 
gentamycin C1 was subjected to a series ofNMR experiments including one-dimensional 
proton experiments and two-dimensional gCOSY, TOCSY, NOESY, and ROESY 
experiments. The data from these experiments allowed for the assignment of its NMR 
spectrum and for obtaining its lowest energy conformation or solution. 
Introduction 
The fight against bacterial infections has been going on for many years, and with 
the advent of antibiotics, man supposedly made a significant step toward conquering 
bacterial illnesses. The first antibiotic was penicillin followed by the discovery of 
streptomycin in 1944, and since then a host of related medicines has followed. 
Unfortunately resistant organisms also followed. In fact multi-resistant bacterial strains 
began to be isolated in increasing numbers throughout the 1950s and 1960s. The 
resistance patters arose from clinical antibiotic use and genetic resistance. The resistant 
bacteria were selected for by antibiotic use, and the R plasmids that generally carried the 
resistance allowed the bacteria to gain resistance to newly introduced antibiotics. This 
resistance has also proven to be a larger problem because it occurs in all enteric bacteria 
without species limitations. (Mitsuhashi, 1982) 
As mentioned previously, the second antibiotic to come into the forefront was 
streptomycin, which is a member of the aminoglycoside family of antibiotics. 
Aminoglycosides are characterized by the presence of amino sugars, and because of their 
structural similarities they have similar chemical properties such as their good water 
solubility, poor solubility in organic solvents, and their ability to be very effective at 
treating gram-negative bacterial infections. (Reden, 1979) Eukaryotic cells are mostly 
unaffected by aminoglycosides, but they kill bacteria by binding to the ribosome' s 16S 
RNA subunit. (Tanaka, 1982) This either inhibits protein synthesis or increases codon 
misreading such that an affected bacterium dies. Unfortunately, resistance to this class of 
antibiotics is increasing, and the R plasmids conferring resistance to aminoglycosides has 
a propensity to carry multiple resistance. (Mitsuhashi, 1982, & Cox, 1977) 
The mode of inactivation conferred by these R plasmids is enzymatic. Enzymes 
are produced that acetylate, phosphorylate, or add a nucleotide to the active functional 
groups (amines and hydroxyls) of the amino glycoside, and because of the structural 
similarities of aminoglycosides cross-resistance has also been observed. (Cox, 1977, 
Mitsuhashi, 1982, & Reden, 1979) 
Among the aminoglycosides, gentamycin, discovered by Weinstein in 1963, has 
proven to be very effective. (Cox, 1977) In fact it is hailed as one of the most powerful, 
and the gentamycin C complex, in particular, has been referred to as "the most important 
aminoglycoside in modem therapy." (Reden, 1979) It exhibits significant effectiveness 
against gram-negative bacteria including "Pseudomonas, Proteus, E. coli, Enterobacter, 
Serratia, and Klebsiella." (Reden, 1979) Furthermore, the gentamycin C complex is 
among the largest selling antibiotics as a mixture. (Hooper, 1982) Unfortunately, 
gentamycin resistant organisms are also becoming more prevalent. (Cox, 1977) Their 
widespread use and clinical importance therefore makes the gentamycin C complex a 
primary target of study for information about the mechanism of resistance and for 
obtaining data toward the design of new drugs. This is the reason for the isolation of 
gentamycin C1 - the largest component of the gentamycin C complex. (See Figure 1) 
Figure 1 (Seidl, 1988) 
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Fig. 1 
Structures of gentamicin components. 
Materials and Methods 
The gentamycin sulfate from Sigma was converted into its free base form using 
Amberlite CG-50 according to the method outlined by Vanderhaeghe (Vanderhaeghe, 
1984) and modified according to Marquez (Marquez, 1972). The free base was then 
concentrated down using a rotary evaporator and redissolved into a solution of 1:2: 1 
isopropanol, chloroform, and 17% ammonium hydroxide. 
A silica gel slurry in this solvent system was packed into a 38cm x 3cm glass 
column. The gentamycin free base was then loaded onto this column and eluted with 
1:2: 1 isopropanol, chloroform, and 25% ammonium hydroxide. After checking the 
fractions by TLC using 1: 1: 1 ethanol, acetone, and concentrated ammonium hydroxide 
and ninhydrin for staining, the fractions containing purified gentamycin C1 were dried, 
redissolved in water, and, finally, lyophilized. (Medina, 1995, & Wilson 1973) 
The gentamycin C1 was then redissolved in D20 for one-dimensional proton 
experiments and two-dimensional gCOSY, TOCSY, NOESY, and ROESY proton 
experiments with a Varian 600MHz NMR. 
The results of the two-dimensional proton experiments were used to assign the 
one-dimensional proton spectra of gentamycin C1• The NOESY spectrum was then used 
in conjunction with the Discover software to determine the solution structure of 
gentamycin C1 by simulated annealing. The Discover program was used for the 
simulated annealing process with the Amber forcefield and a dielectric constant of 4.0. 
The consecutive conjugate minimizations and dynamics simulations were done at 400K, 
350K, 300K, 250K, and 200K to allow for sufficient scanning of the energy surface with 
the NOESY constraints in place. These constraints were applied based on the intensity or 
strength of the proton-proton interactions observed in the NOESY spectrum as 1.8A-
2.8A for strong interactions and 1.8A - 4.5A for weak interactions. After the simulated 
annealing was completed, the restraints were removed, and dynamics was run at lOOK 
followed by minimization to 0.001 rmsd to obtain the lowest energy structure within the 
energy minimum obtained by the simulated annealing process. 
Results 
The spectra obtained using the Varian 600MHz NMR allowed for the assignment 
of the one-dimensional proton spectrum seen below. These assignments are summarized 
in Table la, lb, and lc. 
Table 1a - A ring Proton Assignments 
Proton Chemical Shift Proton Chemical Shift 
(ppm) (ppm) 
HI' 5.441 H5' 3.327 
H2' 3.141 H6' 3.627 
H3' 1.821 HT 1.284 
H4' 1.920 
Table 1 b - B ring Proton Assignments 
Proton Chemical Shift Proton Chemical Shift 
(ppm) (ppm) 
HI ? H4 3.404 
H2a 2.020 H5 3.716 
H2e 1.544 H6 4.069 
H3 2.963 
Table Ic - C ring Assignments 
Proton Chemical Shift Proton Chemical Shift 
(ppm) (ppm) 
HI" 5.119 H4"-methyl ? 
H2" 3.969 HS" ? 
H3" 2.963 
The structure of gentamycin CI was drawn into Discover, and nine random 
structures were created by running dynamics on the basic gentamycin CI structure at 
600K. These structures were then subjected to simulated annealing to obtain their lowest 
energy conformations based on the proton-proton interaction constraints from the NESY 
experiment. These constraints are summarized in Table 2, and Figure 2 shows random 
structures two through nine superimposed after the simulated annealing process. 
Table 2 - NOESY Constraints 
Protons Interaction Protons Interaction Protons Interaction 
Strength Strength Strength 
HI' -H4 Strong HI' - H2' Weak H2 - H6 Weak 
H4-H6 Very Strong HI" - H2" Weak H3 - H4 Weak 
H7' -HS' Strong H2" - H3" Weak H4 - HS Weak 
Figure 2 
Discussion 
The purpose of purifying gentamycin C1 from the other components of the 
gentamycin complex was to assign its proton spectrum and use that data to obtain its 
solution structure. The NOESY constraints used to find the lowest energy conformation 
from the nine random structures of gentamycin C1 that were generated revealed two 
distinct conformations. The major conformation was exhibited by six of the nine 
conformations where the B ring and C ring exhibited great agreement between structures. 
The A ring of these six structures also showed good alignment, and this indicates one 
major structure. Tow ofthe other conformations also had good alignment of the Band C 
rings; however, these two conformations had the A ring aligned perpendicular to the 
other conformer. The final structure exhibited almost no agreement with the other eight 
conformers, and its B ring appeared to be in a chair-flip relative to the other conformers. 
The presence of a major and a minor conformation along with the agreement of 
each of the rings within these conformations is not entirely unheard of; however, these 
results are not definitive. Many more random structures of gentamycin C1 would need to 
be subjected to simulated annealing for the assertion/assumption that there are two 
primary conformers to be proven. Current data cannot be considered to be statistically 
significant. 
After creating a larger pool of structures to determine the solution structure of 
gentamycin C1, this data will be used to compare the free structure to an enzyme bound 
structure of gentamycin C1. The NOESY constraints for the enzyme bound structure will 
then be used in drug-design. Gentamycin was chose for this instead of one of the more 
easily purified aminoglycoside antibiotics because it binds more tightly with the 
detoxifying enzymes, and data from more tightly binding species are needed to gather 
data for drug-design. Fast-exchange NMR cannot be used, and because of gentamycin's 
stronger binding properties, it is an ideal candidate for enzyme bound NMR studies and 
drug design. 
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